M
7.31
-0.30 (-3.89%)
| Previous Close | 7.61 |
| Open | 7.60 |
| Volume | 141,417 |
| Avg. Volume (3M) | 465,388 |
| Market Cap | 588,385,024 |
| Price / Earnings (Forward) | 1.61 |
| Price / Sales | 15.70 |
| Price / Book | 208.46 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2025 |
| Operating Margin (TTM) | -2,159.71% |
| Diluted EPS (TTM) | -2.31 |
| Quarterly Revenue Growth (YOY) | 176.30% |
| Total Debt/Equity (MRQ) | 244.35% |
| Current Ratio (MRQ) | 1.52 |
| Operating Cash Flow (TTM) | -104.58 M |
| Levered Free Cash Flow (TTM) | -53.25 M |
| Return on Assets (TTM) | -37.28% |
| Return on Equity (TTM) | -216.14% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | MeiraGTx Holdings plc | Mixed | Bullish |
AIStockmoo Score
-0.8
| Analyst Consensus | 2.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | -2.0 |
| Average | -0.75 |
|
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 24.27% |
| % Held by Institutions | 60.04% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Perceptive Advisors Llc | 30 Jun 2025 | 12,626,103 |
| Sanofi | 30 Jun 2025 | 12,197,737 |
| Johnson & Johnson | 30 Jun 2025 | 6,641,064 |
| Prosight Management, Lp | 30 Jun 2025 | 4,587,423 |
| Rubric Capital Management Lp | 30 Jun 2025 | 3,726,451 |
| 683 Capital Management, Llc | 30 Jun 2025 | 2,690,000 |
| Knoll Capital Management, Llc | 30 Jun 2025 | 1,250,000 |
| Erste Asset Management Gmbh | 30 Jun 2025 | 789,702 |
| 22Nw, Lp | 30 Jun 2025 | 586,519 |
| 52 Weeks Range | ||
| Median | 35.00 (378.54%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Chardan Capital | 15 Aug 2025 | 35.00 (378.54%) | Buy | 8.17 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 14 Aug 2025 | Announcement | MeiraGTx Reports Second Quarter 2025 Financial and Operational Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |